The Somatostatin Analog SMS 201-995 Induces Long-Acting Inhibition of Growth Hormone Secretion without Rebound Hypersecretion in Acromegalic Patients*

Lamberts, Steven W. J.; Oosterom, R.; Neufeld, Michel; Pozo, E. del

doi:10.1210/jcem-60-6-1161

Cited by 177 publications

(68 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In group II, tile initial inhibition of GH and IGF-I secretion with 3 x 100 lxg octreotide was only retained in 3 cases (13,15,16), whereas in 4 cases (18,20,22,23) the same therapeutic effect was retrieved by increasing the dose. In 5 cases (14,17,19,21,24), the increase of the octreotide dose to 3 • 500 Ixg could not correct the progressive hormonal deterioration but still maintained GH and IGF-I levels below" pretreatment values.…”

Section: Resultsmentioning

confidence: 95%

See 1 more Smart Citation

Effect of treatment with octreotide on the morphology of growth hormone—secreting pituitary adenomas: Study of 24 cases

et al. 1991

View full text Add to dashboard Cite

rTwenty-four acromegalic patients were treated with octreotide subcutaneously for periods of 3 to 6 weeks (group I, 12 cases) or 6 months (group II, 12 cases) before transsphenoidal surgery. Radiological studies performed in 19 patients before and at the end of this treatment period revealed no changes in 8 cases. In 8 other cases, a slight reduction in tumor size was observed, and in 3 cases an important shrinkage was documented. At surgery, the adenoma-.: tous tissue appeared softer than in nonpretreated patients, facilitating the operation. Pathological examination revealed widening of perivascular spaces with accumulation of fibrous tissue and more crinophagy than in nonpretreated patients but failed to reveal morphologi-:; tally pronounced cell involution as observed in prolactin-producing adenomas treated with dopamine agonists. No significant difference in frequency or extent of cellular changes was 9 noted between the two groups. These morphological findings seem to be more consistent with a functional inhibition of growth hormone release than with cellular alterations induced by octreotide. Endocr Pathol 2" 123-131, 1991, 9 L

show abstract

Section: Resultsmentioning

confidence: 95%

“…Recently, a new somatostatin analog, octreotide (Sandostatin, Sandoz Ltd., Basel, Switzerland), with a marked and prolonged inhibitory effect on GH secretion, became available for clinical use [5,13,15]. In this article, we report data recorded from 24 acromegalic patients treated with octreotide before transsphenoidal surgery.…”

mentioning

confidence: 99%

Effect of treatment with octreotide on the morphology of growth hormone—secreting pituitary adenomas: Study of 24 cases

et al. 1991

View full text Add to dashboard Cite

show abstract

“…A recently developed octapeptide analog of somatostatin, SMS 201-995 (Sandostatin~), appears to have a very potent and long-acting inhibitory effect on growth hormone secretion (Bauer et al, 1982;Lamberts et al, 1985). There is a recent review (Lamberts, 1986) of the effects of SMS 201-995 on GH release, and its possible application in the treatment of gastrointestinal disorders, diabetes mellitus and oncology, but so far little is known about its influence on the central nervous system or its behavioral effects.…”

Section: Introductionmentioning

confidence: 99%

Excessive grooming induced by somatostatin or its analog SMS 201-995

Greidanus

Maigret

Krechting

1987

European Journal of Pharmacology

View full text Add to dashboard Cite

Intracerebroventricular (i.c.v.) administration of somatostatin or SMS 201-995 induces excessive grooming behavior in rats. The grooming inducing effect of somatostatin is rather weak, as doses of 300 ng or less did not result in increased total grooming scores. In contrast a dose of 10 ng SMS 201-995 already significantly increased the total grooming scores. However, doses of 100 ng and more did not further increase the total grooming scores reached with a 50 ng dose of this peptide. Systemic administration of SMS 201-995 in doses up to 900 ~tg did not result in excessive grooming behavior. Fhe patterns of excessive grooming induced by i.c.v. SMS 201-995 and somatostatin were characterized by a predominant display of scratching. Since peptide-induced scratching is mainly due to activation of opiate receptor systems it is suggested that opiate receptors are involved in the behavioral response to SMS 201-995 and somatostatin administration. This suggestion is further supported by the suppressive effect of naloxone on excessive grooming induced by these peptides. Haloperidol and neurotensin also suppress the excessive grooming induced by somatostatin but not that induced by SMS 201-995. Finally, tolerance developed to the grooming-inducing effect of SMS 201-995 and somatostatin. In addition there was cross tolerance between somatostatin and SMS 201-995.Somatostatin; SMS 201-995; Grooming behavior

show abstract

“…Rebound hypersecretion of hormones rarely occurs after octreotide administration, neither in healthy subjects nor in patients with neuroendocrine tumours (Lamberts et al, 1985;Chanson et al, 1993). Octreotide is more selective in inhibiting hormone secretion than the natural SST (Bauer et al, 1982).…”

Section: Introductionmentioning

confidence: 99%

Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma

Robben

Brom

Mol

et al. 2006

Research in Veterinary Science

View full text Add to dashboard Cite

The inhibitory effect of the somatostatin analogue octreotide on the secretion of insulin could be used in the treatment of insulinoma. However, current information on the effectiveness of octreotide in dogs is conflicting. Therefore, the endocrine effects of a single subcutaneous dose of 50 lg octreotide were studied in healthy dogs in the fasting state (n = 7) and in dogs with insulinoma (n = 12).Octreotide did not cause any adverse effects. In healthy dogs in the fasting state, both plasma insulin and glucagon concentrations declined significantly. Basal (non-pulse related) GH and ACTH concentrations were not affected. A slight but significant decrease in the plasma glucose concentrations occurred.Dogs with insulinoma had significantly higher baseline insulin concentrations and lower baseline glucose concentrations than healthy dogs in the fasting state. Plasma glucagon, GH, ACTH, and cortisol concentrations did not differ from those in healthy dogs. Baseline plasma insulin concentrations decreased significantly in dogs with insulinoma after octreotide administration, whereas plasma concentrations of glucagon, GH, ACTH, and cortisol did not change. In contrast to the effects in the healthy dogs, in the dogs with insulinoma plasma glucose concentrations increased.Thus, the consistent suppression of plasma insulin concentrations in dogs with insulinoma, in the absence of an suppressive effect on counter-regulatory hormones, suggests that further studies on the effectiveness of slow-release preparations in the long-term medical treatment of dogs with insulinoma are warranted.

show abstract

The Somatostatin Analog SMS 201-995 Induces Long-Acting Inhibition of Growth Hormone Secretion without Rebound Hypersecretion in Acromegalic Patients*

Cited by 177 publications

References 6 publications

Effect of treatment with octreotide on the morphology of growth hormone—secreting pituitary adenomas: Study of 24 cases

Effect of treatment with octreotide on the morphology of growth hormone—secreting pituitary adenomas: Study of 24 cases

Excessive grooming induced by somatostatin or its analog SMS 201-995

Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma

Contact Info

Product

Resources

About